Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis

Minimal Change Nephrotic Syndrome vs Acute Post-Infectious Glomerulonephritis

Glomerular diseases in children typically manifest as either nephrotic syndrome (nephrotic-range proteinuria with hypoalbuminemia, or edema when albumin is unavailable) or nephritic syndrome (characterized by glomerular hematuria, hypertension, mild-to-moderate edema, and oliguric renal dysfunction). Differentiating between these presentations is essential for clinical decision-making on the European Board of Paediatrics examination and in emergency practice.

---

Comparison: Nephrotic vs Nephritic Syndromes

---

Minimal Change Nephrotic Syndrome (MCNS)

Minimal change disease (MCD) represents 85% to 90% of all idiopathic nephrotic syndrome cases in children between 1 and 10 years of age, with a peak incidence between 2 and 6 years and a male-to-female ratio of 2:1.

Pathophysiology and Histopathology

• Immune-Mediated Podocyte Injury: MCD involves immune dysregulation and altered podocyte slit-diaphragm function. T-cell-associated cytokines and circulating permeability factors have been implicated; B-cell-derived antinephrin autoantibodies are also found in a subset of patients. These pathways disrupt podocyte structure and increase albumin permeability.
• Loss of Polyanionic Charge: Sialoproteins and heparan sulfate proteoglycans in the glomerular basement membrane (GBM) lose their net negative charge, permitting massive transudation of negatively charged plasma proteins (predominantly albumin) into Bowman's space.
• Renal Histopathology:
  • Light Microscopy (LM): Glomeruli appear completely normal (hence "minimal change"); tubules may show lipid droplet accumulation (historical term lipoid nephrosis).
  • Immunofluorescence (IF): Negative; absence of significant immunoglobulin or complement deposits.
  • Electron Microscopy (EM): The hallmark diagnostic feature is diffuse effacement (flattening and retraction) of the podocyte foot processes (pedicels) across the capillary loops, with condensation of the actin cytoskeleton.

   NORMAL PODOCYTE ARCHITECTURE                  EFFACED FOOT PROCESSES (MCD)

        Podocyte Cell Body                            Podocyte Cell Body
             /      \                                      |      |
       Primary Foot Processes                        Continuous, flattened
             |      |                                podocyte layer without
       Interdigitating Slit Diaphragm               discrete filtration slits
       [===]  [===]  [===]  [===]                   =========================
  -----------------------------------          -----------------------------------
    Glomerular Basement Membrane                 Glomerular Basement Membrane
  -----------------------------------          -----------------------------------
         Fenestrated Endothelium                      Fenestrated Endothelium
             Capillary Lumen                              Capillary Lumen

Definition and Characteristic Clinical Features

Nephrotic-range proteinuria plus albumin below 30 g/L defines nephrotic syndrome; edema may substitute when albumin is unavailable. Edema and hyperlipidemia are characteristic associated features.

1. Heavy (Nephrotic-Range) Proteinuria:
   • Early-morning urine protein:creatinine ratio (uPCR) $\ge 200\text{ mg/mmol}$ (or $\ge 2.0\text{ mg/mg}$). In adults, equivalent to $>3.5\text{ g/24h}$; in children, $>40\text{ mg/m}^2\text{/hour}$ or $>50\text{ mg/kg/day}$.
   • Urine dipstick demonstrates persistent $3+$ or $4+$ protein ($\ge 300\text{ to }1000\text{ mg/dL}$).
2. Hypoalbuminemia:
   • Serum albumin $<30\text{ g/L}$ (reference: 35–50 g/L), frequently dropping below $15\text{ g/L}$.
3. Generalized Edema:
   • Insidious onset, typically beginning as periorbital edema upon morning awakening (frequently misdiagnosed as allergic conjunctivitis or seasonal allergy), which gravitates during the day to dependent regions (pretibial, ankles, scrotum, labia) and expands into severe ascites and pleural effusions.
4. Hyperlipidemia:
   • Markedly elevated total cholesterol, LDL, and triglycerides.
   • Mechanism: Hypoalbuminemia and reduced oncotic pressure stimulate non-specific hepatic lipid synthesis (apolipoprotein B-100), combined with impaired peripheral lipoprotein clearance due to urinary excretion of lipoprotein lipase co-factors (apolipoprotein C-II) and regulatory enzymes.

---

European Standard Corticosteroid Regimens

Because more than 85% of children presenting between 1 and 10 years of age have steroid-responsive MCD, an empirical trial of corticosteroids without a prior renal biopsy is the standard international standard of care.

Initial Episode Induction Regimen (KDIGO / ESPN Consensus)

• Induction Phase (Daily Therapy):
  • Oral Prednisolone: $60\text{ mg/m}^2\text{/day}$ (or $2\text{ mg/kg/day}$, maximum $60\text{ mg/day}$) administered as a single morning dose for 4 to 6 weeks (4 weeks in an 8-week course, or 6 weeks in a 12-week course).
• Consolidation Phase (Alternate-Day Therapy):
  • Alternate-Day Prednisolone: $40\text{ mg/m}^2$ (or $1.5\text{ mg/kg}$, maximum $40\text{ mg}$) administered on alternate mornings for 4 weeks after the 4-week daily course, or 6 weeks after the 6-week daily course.
• End of Initial Course:
  • Stop after the chosen 8- or 12-week course; do not add a routine taper during alternate-day dosing.

Clinical Definitions of Steroid Responsiveness

• Complete Remission: Morning urine dipstick negative or trace for protein, or uPCR $\le 20\text{ mg/mmol}$ ($\le 0.2\text{ mg/mg}$), for 3 consecutive days.
• Steroid-Sensitive Nephrotic Syndrome (SSNS): Attainment of complete remission within 4 weeks of initiating full-dose daily corticosteroid therapy ($>90\%$ of children with MCD).
• Relapse: Urine dipstick $\ge 3+$ protein or uPCR $\ge 200\text{ mg/mmol}$ for 3 consecutive days after previous complete remission, with or without recurrent edema.
• Frequently Relapsing Nephrotic Syndrome (FRNS): $\ge 2$ relapses in the first 6 months after initial remission, OR $\ge 3$ relapses in any subsequent 12-month period.
• Steroid-Dependent Nephrotic Syndrome (SDNS): Two consecutive relapses during recommended prednisolone treatment for the first episode or a relapse, or within 14 days of stopping it.
• Steroid-Resistant Nephrotic Syndrome (SRNS): Failure to achieve complete remission after 4 weeks of daily prednisolone ($60\text{ mg/m}^2\text{/day}$).

Management of Steroid Resistance (SRNS)

When a child meets criteria for SRNS:

1. Renal Biopsy and Genetic Evaluation: Usually obtain a biopsy to identify the lesion, commonly FSGS or another podocytopathy, and exclude other glomerular disease. A prompt, definitive monogenic diagnosis may make biopsy unnecessary.
2. Genetic Testing: Screen for monogenic podocytopathies (NPHS1 [nephrin], NPHS2 [podocin], WT1, LAMB2, PLCE1). Identifying a causative monogenic mutation dictates cessation of futile, toxic immunosuppression and guides renal transplantation planning (monogenic forms rarely recur post-transplant).
3. Second-Line Immunosuppression: In non-genetic SRNS, initiate Calcineurin Inhibitors (CNIs)—either Tacrolimus (0.1–0.2 mg/kg/day targeting trough 5–10 ng/mL) or Cyclosporine (4–5 mg/kg/day targeting trough 60–150 ng/mL; KDIGO 2025) combined with low-dose alternate-day steroids and ACE inhibitors for antiproteinuric effect.

---

Life-Threatening Complications and Acute Management

Children with active nephrotic syndrome are prone to catastrophic acute complications requiring immediate recognition.

1. Intravascular Hypovolemia and Shock

Although nephrotic children exhibit massive fluid retention (third-space edema and ascites), effective circulating arterial blood volume (EABV) may be critically depleted due to profound hypoalbuminemia ($<15\text{ g/L}$) causing transcapillary fluid shift into interstitial spaces.

• Clinical Signs of Nephrotic Hypovolemia:
  • Severe diffuse abdominal pain (from mesenteric arterial vasoconstriction and intestinal hypoperfusion)
  • Tachycardia, cool mottled extremities, delayed capillary refill ($>3\text{ seconds}$)
  • Narrow pulse pressure, postural dizziness, or late uncompensated hypotension
  • Marked oliguria with elevated urinary specific gravity and high hematocrit (hemoconcentration)
• EMERGENCY RESUSCITATION PROTOCOL:
  • In hypovolemic shock, give IV 4% or 5% human albumin, 20 mL/kg over 20–30 minutes, with frequent cardiovascular reassessment and urgent specialist support. Isotonic saline is an alternative if dilute albumin is unavailable.
  • Withhold furosemide during shock. Restore circulating volume first; monitor perfusion, blood pressure, urine output and signs of pulmonary edema.
  • For intravascular contraction without shock, 20–25% albumin, 0.5–1 g/kg over 4–6 hours, may be used. Add IV furosemide (1–2 mg/kg) only if circulating volume has been restored and diuresis is needed.

2. Thromboembolism

Nephrotic syndrome is an intensely prothrombotic state, with thromboembolic complications occurring in 2% to 5% of pediatric patients.

• Pathophysiological Mechanisms:
  • Massive urinary loss of endogenous anticoagulants: Antithrombin III (AT-III), Protein S, and plasminogen.
  • Hepatic overproduction of procoagulant proteins: Fibrinogen, Factor V, Factor VIII, and Factor X.
  • Thrombocytosis ($>500 \times 10^9\text{/L}$) and platelet hyperaggregability.
  • Hemoconcentration (elevated hematocrit due to third-space plasma loss).
  • Immobility secondary to severe edema.
• Common Sites and Presentations:
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
  • Renal Vein Thrombosis (RVT): Sudden macroscopic hematuria, unilateral or bilateral flank mass, worsening AKI, and sudden decline in platelet count.
  • Sagittal Sinus Thrombosis: Persistent severe headache, intractable vomiting, papilledema, and seizures.
• Prevention & Management: Avoid femoral venipunctures; avoid excessive diuresis; maintain hydration and ambulation. Confirmed thrombosis is managed with therapeutic low-molecular-weight heparin (enoxaparin) for 3 to 6 months.

3. Serious Bacterial Infections

Infection represents the primary cause of mortality in pediatric nephrotic syndrome.

• Mechanisms of Immune Vulnerability:
  • Massive urinary loss of Immunoglobulin G (IgG).
  • Urinary wasting of alternative complement pathway components, particularly Properdin Factor B, crippling opsonization of encapsulated bacteria.
  • Iatrogenic immunosuppression from high-dose corticosteroids.
• Spontaneous Bacterial Peritonitis (SBP):
  • The quintessential nephrotic infection. Overwhelmingly caused by Streptococcus pneumoniae (Pneumococcus), followed by Gram-negative enteric bacilli (E. coli).
  • Presentation: Acute onset high fever, severe diffuse abdominal pain, abdominal tenderness, guarding, rebound tenderness, and vomiting in a child with ascites.
  • Diagnostic workup: Blood cultures and diagnostic paracentesis (ascitic fluid neutrophil count $>250/\mu\text{L}$). Immediate empiric treatment with IV Cefotaxime or Ceftriaxone.
• Immunization & Prophylaxis Recommendations:
  • Pneumococcal vaccination: Complete routine and additional risk-group vaccination according to the national schedule, age and previous doses. PPSV23 is not automatically required after PCV20.
  • Varicella Zoster: Live vaccines (MMR, Varicella) are STRICTLY CONTRAINDICATED while receiving daily high-dose steroids. Varicella vaccine should be administered during stable remission when off steroids for at least 1 to 3 months. If an unimmunized child on steroids is exposed to chickenpox, administer Varicella Zoster Immunoglobulin (VZIG) within 96 hours, or start oral acyclovir.
  • Routine Penicillin V prophylaxis is recommended during active relapses in many European centers.

---

Acute Post-Streptococcal Glomerulonephritis (APSGN)

APSGN is the prototype of acute endocapillary proliferative glomerulonephritis, occurring after an infection with nephritogenic strains of Group A $\beta$-hemolytic Streptococcus (GAS, Streptococcus pyogenes).

Pathophysiology and Latency

• Nephritogenic Streptococcal Antigens: Specifically SpeB (streptococcal pyrogenic exotoxin B) and NAPlr (nephritis-associated plasmin receptor). These antigens deposit in the glomerular mesangium and subepithelial space, triggering in situ immune complex formation with host IgG antibodies.
• Alternative Pathway Complement Activation: Marked consumption of complement protein C3, recruiting circulating neutrophils, macrophages, and stimulating endocapillary cell proliferation that occludes the glomerular capillary lumens, causing an abrupt drop in GFR.
• Clinical Latency Period:
  • Post-Pharyngeal: 1 to 2 weeks (7 to 14 days) following streptococcal pharyngitis/tonsillitis.
  • Post-Cutaneous: 3 to 6 weeks (21 to 42 days) following streptococcal impetigo or pyoderma.

Clinical Presentation: The Classic Nephritic Syndrome

1. Glomerular Hematuria: Present in 100% of cases. Macroscopic hematuria occurs in 30–50%, classically described as "tea-colored", "cola-colored", or smoky brownish-red urine without blood clots. Urinalysis reveals $>80\%$ dysmorphic red blood cells (acanthocytes) and pathognomonic red blood cell casts.
2. Hypertension: Present in 60–80% of patients. Results directly from fluid retention and hypervolemia rather than hyper-reninemia. May precipitate hypertensive encephalopathy (headache, vomiting, visual blurring, seizures) or acute congestive cardiac failure.
3. Edema: Typically mild-to-moderate periorbital and facial puffiness upon morning waking, accompanied by dependent ankle swelling.
4. Oliguria: Variable reduction in urine output ($<0.5\text{ mL/kg/hour}$) with transient elevation of serum creatinine.

Laboratory Diagnosis and Complement Dynamics

• Evidence of Preceding Streptococcal Infection:
  • Antistreptolysin O (ASO) titer: Elevated in $>80\%$ of post-pharyngeal GN, but frequently normal in post-impetigo cases due to cutaneous lipid inhibition of ASO response.
  • Anti-DNase B titer: Significantly more sensitive for post-impetigo GN (elevated in $>90\%$ of cutaneous cases).
• Serum Complement Profile:
  • Depressed Serum C3: Characteristically reduced below $0.5\text{ g/L}$ in $>90\%$ of acute cases due to intense alternative pathway activation.
  • Normal Serum C4: C4 is typically normal or only mildly depressed, reflecting sparing of the classical pathway.
• Complement Follow-up and Biopsy Consideration:
  • In APSGN, serum C3 usually normalizes within 6 to 8 weeks. Repeat C3 and renal function at the follow-up review.
  • Persistently low C3 at 8 weeks warrants prompt paediatric nephrology review and consideration of biopsy, especially with abnormal renal function, significant proteinuria or an atypical course. Consider C3 glomerulopathy, MPGN or lupus nephritis.

Renal Histopathology

• Light Microscopy: Diffuse, global endocapillary proliferative and exudative glomerulonephritis; glomeruli are enlarged, hypercellular, and infiltrated by neutrophils and monocytes, obliterating capillary lumens.
• Immunofluorescence: Granular deposition of C3 and IgG along the glomerular basement membrane and mesangium, creating the classic "starry sky" or "garland" pattern.
• Electron Microscopy: Pathognomonic large, dome-shaped subepithelial electron-dense deposits ("humps").

                                [Acute Glomerulonephritis]
                                             |
                 +---------------------------+---------------------------+
                 |                                                       |
       [Depressed Serum C3]                                     [Normal Serum C3]
                 |                                                       |
     +-----------+-----------+                               +-----------+-----------+
     |                       |                               |                       |
[APSGN]                  [MPGN / SLE]                   [IgA Nephropathy]        [ANCA Vasculitis /]
- C3 usually recovers    - Persistent low C3           - Synpharyngitic            Anti-GBM Disease
- High ASO/DNase B       - Review; consider biopsy     - Normal C3/C4              - Systemic features

Supportive Management and Prognosis

There is no specific immunomodulatory therapy for APSGN; management is entirely supportive:

• Fluid and Sodium Restriction: Restrict fluids strictly to insensible losses ($400\text{ mL/m}^2\text{/day}$) plus the previous day's urine output. Enforce a strict low-sodium diet.
• Loop Diuretics: Oral or intravenous Furosemide ($1\text{ to }2\text{ mg/kg}$) is first-line therapy for hypervolemia, symptomatic edema, and volume-dependent hypertension.
• Antihypertensive Agents: If hypertension persists despite adequate loop diuresis, administer oral calcium channel blockers (e.g., Amlodipine or Isradipine).
• Contraindicated Medications: ACE inhibitors (e.g., enalapril) and ARBs are strictly contraindicated in the acute phase of APSGN, as efferent arteriolar vasodilation causes an abrupt fall in GFR and severely exacerbates hyperkalaemia in an already oliguric kidney.
• Antibiotic Therapy: A 10-day course of oral penicillin or amoxicillin is indicated only to eradicate persistent streptococcal colonization and prevent spread to household contacts; antibiotics do not influence the severity, course, or resolution of the established glomerulonephritis.
• Prognosis: Exceptional in children. Over 95% make a complete, spontaneous recovery. Diuresis typically begins within 5 to 7 days, blood pressure normalizes within 1 to 2 weeks, and serum C3 normalizes within 6 to 8 weeks. Microscopic hematuria may persist for up to 1 to 2 years and is clinically benign if proteinuria has resolved.